Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress.

Ronca R, Ghedini GC, Maccarinelli F, Sacco A, Locatelli SL, Foglio E, Taranto S, Grillo E, Matarazzo S, Castelli R, Paganini G, Desantis V, Cattane N, Cattaneo A, Mor M, Carlo-Stella C, Belotti A, Roccaro A, Presta M, Giacomini A.

Cancer Res. 2020 Feb 24. pii: canres.2714.2019. doi: 10.1158/0008-5472.CAN-19-2714. [Epub ahead of print]

PMID:
32094301
2.

Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis.

Capo V, Penna S, Merelli I, Barcella M, Scala S, Basso-Ricci L, Draghici E, Palagano E, Zonari E, Desantis G, Uva P, Cusano R, Sergi Sergi L, Crisafulli L, Moshous D, Stepensky P, Drabko K, Kaya Z, Unal E, Gezdirici A, Menna G, Serafini M, Aiuti A, Locatelli SL, Carlo-Stella C, Schulz AS, Ficara F, Sobacchi C, Gentner B, Villa A.

Haematologica. 2020 Jan 16. pii: haematol.2019.238261. doi: 10.3324/haematol.2019.238261. [Epub ahead of print]

3.

Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis.

Palagano E, Muggeo S, Crisafulli L, Tourkova IL, Strina D, Mantero S, Fontana E, Locatelli SL, Monari M, Morenghi E, Carlo-Stella C, Barnett JB, Blair HC, Vezzoni P, Villa A, Sobacchi C, Ficara F.

Bone Rep. 2020 Jan 7;12:100242. doi: 10.1016/j.bonr.2020.100242. eCollection 2020 Jun.

4.

A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.

Carlo-Stella C, Delarue R, Scarfo L, Barde PJ, Nair A, Locatelli SL, Morello L, Magagnoli M, Vakkalanka S, Viswanadha S, Ferreri AJM.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):78-86. doi: 10.1016/j.clml.2019.10.013. Epub 2019 Oct 23.

PMID:
31761713
5.

Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.

Righi M, Locatelli SL, Carlo-Stella C, Presta M, Giacomini A.

Sci Rep. 2018 Nov 30;8(1):17520. doi: 10.1038/s41598-018-35788-4.

6.

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.

Locatelli SL, Careddu G, Serio S, Consonni FM, Maeda A, Viswanadha S, Vakkalanka S, Castagna L, Santoro A, Allavena P, Sica A, Carlo-Stella C.

Clin Cancer Res. 2019 Feb 1;25(3):1098-1112. doi: 10.1158/1078-0432.CCR-18-1133. Epub 2018 Oct 23.

7.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D.

Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15.

PMID:
29449275
8.

Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.

Pierdominici M, Maselli A, Locatelli SL, Ciarlo L, Careddu G, Patrizio M, Ascione B, Tinari A, Carlo-Stella C, Malorni W, Matarrese P, Ortona E.

Oncotarget. 2017 Jan 31;8(5):8522-8535. doi: 10.18632/oncotarget.14338.

9.

Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.

Locatelli SL, Careddu G, Stirparo GG, Castagna L, Santoro A, Carlo-Stella C.

Sci Rep. 2016 Oct 21;6:35745. doi: 10.1038/srep35745.

10.

The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

Locatelli SL, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A, Carlo-Stella C.

Leukemia. 2016 Dec;30(12):2402-2405. doi: 10.1038/leu.2016.224. Epub 2016 Aug 8. No abstract available.

PMID:
27499137
11.

DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiation.

Cattaneo P, Kunderfranco P, Greco C, Guffanti A, Stirparo GG, Rusconi F, Rizzi R, Di Pasquale E, Locatelli SL, Latronico MV, Bearzi C, Papait R, Condorelli G.

Cell Death Differ. 2016 Apr;23(4):555-64. doi: 10.1038/cdd.2014.199. Epub 2014 Dec 19.

12.

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM.

Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19.

13.

YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.

Pennati M, Sbarra S, De Cesare M, Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C, Gianni AM, Zaffaroni N.

Int J Cancer. 2015 Jan 15;136(2):299-309. doi: 10.1002/ijc.28993. Epub 2014 Jun 5.

14.

BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C.

Leukemia. 2014 Sep;28(9):1861-71. doi: 10.1038/leu.2014.81. Epub 2014 Feb 24.

PMID:
24561519
15.

Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.

Pierdominici M, Barbati C, Vomero M, Locatelli SL, Carlo-Stella C, Ortona E, Malorni W.

FASEB J. 2014 Feb;28(2):524-35. doi: 10.1096/fj.13-235655. Epub 2013 Nov 6. Review.

PMID:
24196588
16.

Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies.

Marconi M, Ascione B, Ciarlo L, Vona R, Garofalo T, Sorice M, Gianni AM, Locatelli SL, Carlo-Stella C, Malorni W, Matarrese P.

Cell Death Dis. 2013 Oct 17;4:e863. doi: 10.1038/cddis.2013.389.

17.

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

Carlo-Stella C, Locatelli SL, Giacomini A, Cleris L, Saba E, Righi M, Guidetti A, Gianni AM.

PLoS One. 2013 Apr 19;8(4):e61603. doi: 10.1371/journal.pone.0061603. Print 2013.

18.

Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.

Giacomini A, Righi M, Cleris L, Locatelli SL, Mitola S, Daidone MG, Gianni AM, Carlo-Stella C.

Angiogenesis. 2013 Jul;16(3):707-22. doi: 10.1007/s10456-013-9348-7. Epub 2013 Apr 20.

PMID:
23605004
19.

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.

Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.

Leukemia. 2013 Aug;27(8):1677-87. doi: 10.1038/leu.2013.28. Epub 2013 Jan 30.

PMID:
23360848
20.

Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM.

Br J Haematol. 2012 Jul;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x. Epub 2012 May 10.

PMID:
22571717
21.

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM.

Cancer. 2011 Nov 15;117(22):5074-84. doi: 10.1002/cncr.26182. Epub 2011 May 12.

Supplemental Content

Loading ...
Support Center